Core Viewpoint - BioStem Technologies, Inc. is showcasing its innovative placental-derived products for chronic wound care at the Symposium for Advanced Wound Care (SAWC) Spring meeting, emphasizing collaboration with Venture Medical, LLC to enhance patient management and treatment outcomes [1][2][3]. Company Overview - BioStem Technologies focuses on the development, manufacturing, and commercialization of placental-derived products aimed at advanced wound care [1][13]. - The company utilizes its proprietary BioREtain processing method to preserve the natural properties of perinatal tissue, ensuring the efficacy of its allografts [11][13]. Partnership Highlights - The collaboration with Venture Medical, LLC aims to streamline the logistics of managing patients requiring skin substitutes for chronic wound treatment [2][3]. - BioStem's leading products, AmnioWrap2 and Vendaje AC, are exclusively available through Venture Medical, which has effectively penetrated the physician office and mobile segments [3]. Event Participation - BioStem will co-exhibit with Venture Medical at the SAWC Spring meeting in Dallas, TX, from April 30 to May 4, 2025, featuring three accepted scientific posters on its advanced allograft portfolio [1][6]. - The booth schedule includes discussions on reimbursement landscapes, mobile wound care practices, and the benefits of BioStem's BioREtain technology [3][8]. Scientific Contributions - Three clinical and scientific posters accepted for presentation will demonstrate favorable outcomes with BioREtain technology and comparisons with competitive products [10]. - Ongoing randomized clinical trials are evaluating the treatment of diabetic foot ulcers and venous leg ulcers, with results expected later this year [10]. Educational Initiatives - A sponsored breakfast symposium titled "Healing Under Pressure: Advancements in Skin Substitutes for Pressure Ulcer Treatment" will address the importance of comprehensive care for patients with chronic wounds [5].